

CURRICULUM VITAE

C. PIERS CLIFFORD MD BA MBBS FRCP



PIERS CLIFFORD
CARDIAC SPECIALIST

PERSONAL:

Name: Christopher Piers Clifford
Date of birth: 9th March 1963
Address: 26, Chiswick Lane, London W4 2JG
Telephone: **Home:** 0208 9954022
Work: 01494 425004
Mobile: 07747 015208
Nationality: British
Marital status: Divorced
GMC Registration No: 3259797

EDUCATION:

1974-1980
Open Scholarship to Christ's Hospital, Horsham, Sussex
1981-1984
Open Scholarship to St. John's College, Oxford
1984-1987
St. Mary's Hospital Medical School, London

QUALIFICATIONS:

1984 – BA Hons (Oxon) First Class
1987 – MB BS (London)
1998 – MD (London)
2000 (February) – CCST Cardiology G(1)M
2007 – FRCP (UK)

PRIZES & AWARDS:

Scholarship to St. John's College, Oxford. October 1982
College Book Prize for Physiological Sciences. July 1984
Prize from the Martin Wronker Fund, Oxford. July 1984
First Class Honours in Physiological Sciences. July 1984

PRESENT APPOINTMENT:

Oct 1999 – Jan 2011
Consultant Cardiologist
Buckinghamshire Hospitals NHS Trust
Imperial Hospitals NHS Trust

CLINICAL EXPERIENCE:

I have been a Consultant Cardiologist for 11 years and have a wide and extensive experience in General Cardiology as well as in coronary intervention. At present I perform 350 angioplasties per year, mainly involving coronary stenting, which places me in the upper decile for interventional procedures in the UK. I have been on a primary angioplasty on call rota at the Hammersmith Hospital for 7 years. I continue to provide a pacing and angiography service.

My other areas of interest are in the mechanisms of hypertension and LVH, as well as a particular interest in the management of atrial fibrillation. I have run hypertension clinics for the last 19 years.

CURRICULUM VITAE

C. PIERS CLIFFORD MD BA MBBS FRCP

RESEARCH EXPERIENCE:

My doctorate investigated the molecular mechanisms of left ventricular hypertrophy in hypertensive adults. Since I became a consultant I have participated in multi-centre trials including IONA, SENIORS and OVERTURE studies. Presently I am involved with the DAPT study in elective stented patients and the EPICOR study in acute coronary syndrome patients. I am PI for the Cynergy registry at Imperial Hospitals NHS Trust and contribute to the Tryton Registry for complex Left Main Stem stenting.

In the last year I have raised funding for 3 trials in coronary intervention. The first involves the use of thrombectomy in primary angioplasty. We aim to elucidate the monocyte subtypes found in the thrombus at the site of myocardial infarction and to investigate whether this helps predict infarct size as measured on MRI and subsequent outcome.

The second is a multi-centre trial of stenting in the elderly population with acute coronary syndromes and the third is in the use of optical coherence tomography in the detection of stent strut coverage with the aim of developing a Clopidogrel cessation clinic for patients who require urgent surgery within a year of receiving drug eluting stents. I employ a full time research nurse at Wycombe funded by NIHR.

MANAGEMENT EXPERIENCE:

I am the Chairman of the Division of Medicine at Buckinghamshire Hospitals NHS Trust and the Clinical Lead for Cardiology.

As cardiology lead I have developed a highly successful unit. We now perform 1400 angiograms, 540 angioplasties and 160 pacemakers through a single catheter laboratory. Prior to my arrival all this work was performed elsewhere leading to delays in treatment and excessive lengths of stay. Our bed stock has diminished by 50% as a result. We generate more income and profit for the Trust as an SDU than any other in the Hospital. I have maintained and developed strong links with our surrounding Tertiary Centres to deliver high quality care to Buckinghamshire patients.

As Chairman of the Division of Medicine I have delivered a 15% reduction in the Medical budget without any loss of service. We have developed our hyperacute services to include daytime primary angioplasty and a HASU. We have streamlined the urgent care pathway to reduce admissions and encourage early discharge through a short stay medical assessment ward.

I had until recently been appointed as head of coronary intervention at Imperial Hospitals NHS Trust. I have extensive experience in procurement of catheter laboratory equipment and have raised £30,000 per year as educational grants for my cardiac staff from industrial sources.

TEACHING EXPERIENCE:

I teach undergraduates from the Oxford Deanery and have an active involvement in the F1/F2 teaching programs. I am a trainer in coronary angioplasty and regularly lecture on interventional cardiology. I am on advisory boards for many different device and pharmaceutical companies.

CURRICULUM VITAE

C. PIERS CLIFFORD MD BA MBBS FRCP

PUBLICATIONS:

- Clifford CP, Cook DWM, Conlon CP et al. 1991.**
Impact of waterborne outbreak of cryptosporidiosis on AIDS and renal transplant patients.
Lancet; 335: 1455-1456 (letter).
- Clifford CP, Nunez DJ. 1996.**
5HT 2a receptor T102C polymorphism and schizophrenia.
Lancet; 347: 1830 (letter).
- Clifford CP, Unwin RJ, Dollery CT, Wilkins MR. 1993.**
Assessment of alpha-adrenoceptor selectivity of Bunazosin Retard in man.
Br J Clin Pharm; 5: 541-542.
- Clifford CP, Nunez DJR. 1996**
Racial differences in the frequency of a restriction site polymorphism of the angiotensin converting enzyme gene.
J Hypertens; 14 (suppl 1): S13.
- Clifford CP. 1994**
Pharmacological treatment of tachycardias.
Postgraduate Doctor; 17: 268-273.
- Clifford CP. 1994.**
Drugs used in the treatment of heart failure.
Postgraduate Doctor 1994; 11: 2-7.
- Donnelly LE, Boyd RS, Clifford CP, Olmos G, Allport JR, Lo G. & MacDermot J. 1994.**
Endogenous substrates and functional role of eukaryotic mono (ADPriboseyl) transferases.
Biochem Pharmac; 48: 1669-1675.
- Nunez DJR, Clifford CP, Al-Mahdawi S, Dutka D. 1996**
Hypertensive cardiac hypertrophy – is genetic variance the missing link.
Br J Clin Pharm; 42 (1): 107-117.
- Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS. 1997.**
Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.
Eur J Clin Pharm; 4: 311-317.
- Adams DA, Murray S, Clifford CP, Rendall NB, Davies DS, Taylor GW. 1997.**
Analysis of terfenadine in human plasma using microbore high-performance liquid chromatography-electrospray ionisation mass spectrometry.
J. Chromatog; 693: 354-351.
- Clifford CP, Eykyn SJ, Oakley CM. 1994.**
Staphylococcal tricuspid valve endocarditis in patients with structurally normal hearts and no evidence of narcotic abuse.
Q J Med; 87: 755-757.
- Clifford CP, Davies GJ. 1993.**
Tuberculosis pericarditis with rapid progression to constriction.
Br Med J; 37: 1052-1054.
- Clifford CP, Nihoyannopoulos P.**
Symptomatology and diagnosis of coronary artery disease
Angiology in Practice. Ed Salmasi.
- Clifford CP. 1998.**
The use of platelet glycoprotein receptor antagonists in coronary artery disease.
Interventional Cardiology Monitor; 5: 30-31.
- Clifford CP, Nunez DJR. 1998.**
Human beta-myosin heavy chain gene mRNA prevalence is inversely related to the degree of methylation of its regulatory elements.
Cardiovasc Res; (3): 736-743.
- Clifford CP, Nunez DJR. 1999.**
Mutation profile in the beta-myosin heavy chain gene in hypertensive heart disease.
Human Mutation (on line).

REFEREES:

Dr Graz Luzzi MD., FRCP.
Medical Director
Buckinghamshire Hospitals NHS Trust
Queen Alexandra Road
High Wycombe
Bucks HP11 2TT

Ms Anne Eden
Chief Executive
Buckinghamshire Hospitals NHS Trust
Queen Alexandra Road
High Wycombe
Bucks HP11 2TT

Graham J Davies, MD., FRCP.
Consultant Cardiologist
Hammersmith Hospital
Du Cane Road
LONDON W12 0NN